A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02006472
Recruitment Status : Completed
First Posted : December 10, 2013
Last Update Posted : August 21, 2018
European Huntington's Disease Network
Huntington Study Group
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 31, 2016
  Actual Study Completion Date : August 31, 2016
  Certification/Extension First Submitted : May 8, 2018